Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical Center
Clinical Infectious Diseases2009Vol. 48(12), pp. 1724–1728
Citations Over TimeTop 1% of 2009 papers
Joshua D. Hartzell, Robert Neff, Julie A. Ake, Robin Howard, Stephen W. Olson, Kristopher Paolino, Mark Vishnepolsky, Amy Weintrob, Glenn Wortmann
Abstract
The incidence of acute renal failure, defined by the risk, injury, or failure criteria of the RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease), in 66 patients who received colistimethate sodium was 45%, and 21% of patients stopped therapy because of nephrotoxicity. The RIFLE criteria should be used in the future to allow for comparison of nephrotoxicity among studies.
Related Papers
- → Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study(2018)82 cited
- → Acute kidney injury after cardiac surgery: A comparison of different definitions(2019)37 cited
- → Rat models of colistin nephrotoxicity: previous experimental researches and future perspectives(2019)16 cited
- → Nephrotoxicity rates related to colistin and evaluation of risk factors(2018)2 cited
- → Nefrotoxicity Caused by Colistin Use: A Single Center Experience(2023)